Intravesical Glycosaminoglycans Experience for Chronic Lower Urinary Tract Pathology Treatment

 

 Permissions and Reprints

Abstract

Objective Intravesical glycosaminoglycans (GAG) treatment is one of the therapeutic options for chronic bladder pathologies and is approved for Bladder Pain Syndrome (BPS), radiation cystitis, and recurrent urinary tract infections (UTIs). The purpose of this study is to describe the demographic characteristics of patients with such pathologies in our population and to evaluate treatment response.

Methods It is a retrospective study of patients with the aforementioned pathologies, who received treatment with GAG. Demographic characteristics and subjective improvement with treatment were evaluated. A bivariate analysis was performed to study possible improvement predictors.

Results 53 patients were evaluated. Of them, 33 (62.3%) with BPS, 12 (22.6%) with recurrent UTIs, and 8 (15.1%) with radiation cystitis. The dose range received was between 4 - 20 instillations, with a median of 6 doses. 67.9% of patients showed improvement of symptoms with treatment, this percentage being even higher for the group of patients with recurrent UTIs (91%). No treatment response predictors were found.

Conclusions Intravesical GAG treatment is a therapeutic alternative for patients with chronic bladder pathologies, with satisfactory results in the medium term. Prospective studies are needed to support the findings of this study.

Publication History

Received: 04 November 2019

Accepted: 06 May 2020

Article published online:
06 October 2020

© 2020. Sociedad Colombiana de Urología. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

• References

• 1 Patnaik SS, Laganà AS, Vitale SG. et al. Etiology, pathophysiology and biomarkers of interstitial cystitis/painful bladder syndrome. Arch Gynecol Obstet 2017; 295 (06) 1341-1359
  CrossrefPubMedGoogle Scholar
• 2 Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology 1997; 49 (5A, Suppl) 111-113
  CrossrefPubMedGoogle Scholar
• 3 Arance I, Ramón de Fata F, Angulo JC. et al. Evidencia disponible relativa a la eficacia de diferentes agentes endovesicales restituidores de glucosaminoglicanos empleados en cistitis intersticial. Actas Urol Esp 2013; 37 (02) 92-99 DOI: 10.1016/j.acuro.2012.10.002 [Internet].
  CrossrefPubMedGoogle Scholar
• 4 Lipovac M, Kurz C, Reithmayr F, Verhoeven HC, Huber JC, Imhof M. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 2007; 96 (03) 192-195
  CrossrefPubMedGoogle Scholar
• 5 Giberti C, Gallo F, Cortese P, Schenone M. Combined intravesical sodium hyaluronate/chondroitin sulfate therapy for interstitial cystitis/bladder pain syndrome: a prospective study. Ther Adv Urol 2013; 5 (04) 175-179
  CrossrefPubMedGoogle Scholar
• 6 Douglas-Moore JL, Goddard J. Current best practice in the management of cystitis and pelvic pain. Ther Adv Urol 2017; 10 (01) 17-22
  CrossrefPubMedGoogle Scholar
• 7 Gülpınar Ö, Esen B, Kayış A, Gökçe Mİ, Süer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol Urodyn 2018; 37 (01) 257-262
  CrossrefPubMedGoogle Scholar
• 8 Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 2011; 22 (04) 401-405
  CrossrefPubMedGoogle Scholar
• 9 Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19 (05) 717-721
  CrossrefPubMedGoogle Scholar
• 10 Cervigni M, Natale F, Nasta L, Padoa A, Voi RL, Porru D. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 2008; 19 (07) 943-947
  CrossrefPubMedGoogle Scholar
• 11 Akbay E, Çayan S, Kılınç C, Bozlu M, Tek M, Efesoy O. The short-term efficacy of intravesical instillation of hyaluronic acid treatment for bladder pain syndrome/interstitial cystitis. Turk J Urol 2018; 45 (02) 129-134
  CrossrefPubMedGoogle Scholar
• 12 Goddard JC, Janssen DAW. Intravesical hyaluronic acid and chondroitin sulfate for recurrent urinary tract infections: systematic review and meta-analysis. Int Urogynecol J Pelvic Floor Dysfunct 2018; 29 (07) 933-942
  CrossrefPubMedGoogle Scholar
• 13 Constantinides C, Manousakas T, Nikolopoulos P, Stanitsas A, Haritopoulos K, Giannopoulos A. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 2004; 93 (09) 1262-1266
  CrossrefPubMedGoogle Scholar
• 14 Gacci M, Saleh O, Giannessi C. et al. Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study. Clin Genitourin Cancer 2016; 14 (05) 444-449 DOI: 10.1016/j.clgc.2016.01.016 [Internet].
  CrossrefPubMedGoogle Scholar
• 15 Samper Ots PM, López Carrizosa C, Rodríguez A. et al. Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival: a five-year follow-up study. Clin Transl Oncol 2009; 11 (12) 828-834
  CrossrefPubMedGoogle Scholar